![Christoph Arnoldner](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Christoph Arnoldner
Corporate Officer/Principal en Acousia Therapeutics GmbH .
Relaciones activas
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
Frank Kalkbrenner | M | - |
Acousia Therapeutics GmbH
![]() Acousia Therapeutics GmbH BiotechnologyHealth Technology Acousia Therapeutics GmbH identifies small molecules for treatment of hearing loss. The firm develops drugs for local application, which will protect hearing function or restore hearing in patients who have lost their hearing ability due to various reasons. It also develops small molecule compounds that trigger regeneration of sensory hair cells and therefore allow casual treatment of sensorineural hearing loss in patients who already lost their hair cells years ago. The company was founded by Hubert Löwenheim and Karl-Heinz Wiesmüller in 2012 and is headquartered in Tübingen, Germany. | 12 años |
Hubert Löwenheim | M | - |
Acousia Therapeutics GmbH
![]() Acousia Therapeutics GmbH BiotechnologyHealth Technology Acousia Therapeutics GmbH identifies small molecules for treatment of hearing loss. The firm develops drugs for local application, which will protect hearing function or restore hearing in patients who have lost their hearing ability due to various reasons. It also develops small molecule compounds that trigger regeneration of sensory hair cells and therefore allow casual treatment of sensorineural hearing loss in patients who already lost their hair cells years ago. The company was founded by Hubert Löwenheim and Karl-Heinz Wiesmüller in 2012 and is headquartered in Tübingen, Germany. | 12 años |
Christoph Antz | M | 63 |
Acousia Therapeutics GmbH
![]() Acousia Therapeutics GmbH BiotechnologyHealth Technology Acousia Therapeutics GmbH identifies small molecules for treatment of hearing loss. The firm develops drugs for local application, which will protect hearing function or restore hearing in patients who have lost their hearing ability due to various reasons. It also develops small molecule compounds that trigger regeneration of sensory hair cells and therefore allow casual treatment of sensorineural hearing loss in patients who already lost their hair cells years ago. The company was founded by Hubert Löwenheim and Karl-Heinz Wiesmüller in 2012 and is headquartered in Tübingen, Germany. | - |
Harald Poth | M | - |
Acousia Therapeutics GmbH
![]() Acousia Therapeutics GmbH BiotechnologyHealth Technology Acousia Therapeutics GmbH identifies small molecules for treatment of hearing loss. The firm develops drugs for local application, which will protect hearing function or restore hearing in patients who have lost their hearing ability due to various reasons. It also develops small molecule compounds that trigger regeneration of sensory hair cells and therefore allow casual treatment of sensorineural hearing loss in patients who already lost their hair cells years ago. The company was founded by Hubert Löwenheim and Karl-Heinz Wiesmüller in 2012 and is headquartered in Tübingen, Germany. | - |
Thomas Hoffmann | M | - |
Acousia Therapeutics GmbH
![]() Acousia Therapeutics GmbH BiotechnologyHealth Technology Acousia Therapeutics GmbH identifies small molecules for treatment of hearing loss. The firm develops drugs for local application, which will protect hearing function or restore hearing in patients who have lost their hearing ability due to various reasons. It also develops small molecule compounds that trigger regeneration of sensory hair cells and therefore allow casual treatment of sensorineural hearing loss in patients who already lost their hair cells years ago. The company was founded by Hubert Löwenheim and Karl-Heinz Wiesmüller in 2012 and is headquartered in Tübingen, Germany. | - |
Karl-Heinz Wiesmüller | M | - |
Acousia Therapeutics GmbH
![]() Acousia Therapeutics GmbH BiotechnologyHealth Technology Acousia Therapeutics GmbH identifies small molecules for treatment of hearing loss. The firm develops drugs for local application, which will protect hearing function or restore hearing in patients who have lost their hearing ability due to various reasons. It also develops small molecule compounds that trigger regeneration of sensory hair cells and therefore allow casual treatment of sensorineural hearing loss in patients who already lost their hair cells years ago. The company was founded by Hubert Löwenheim and Karl-Heinz Wiesmüller in 2012 and is headquartered in Tübingen, Germany. | 12 años |
Christine Lemke | F | - |
Acousia Therapeutics GmbH
![]() Acousia Therapeutics GmbH BiotechnologyHealth Technology Acousia Therapeutics GmbH identifies small molecules for treatment of hearing loss. The firm develops drugs for local application, which will protect hearing function or restore hearing in patients who have lost their hearing ability due to various reasons. It also develops small molecule compounds that trigger regeneration of sensory hair cells and therefore allow casual treatment of sensorineural hearing loss in patients who already lost their hair cells years ago. The company was founded by Hubert Löwenheim and Karl-Heinz Wiesmüller in 2012 and is headquartered in Tübingen, Germany. | - |
Pascal Senn | M | - |
Acousia Therapeutics GmbH
![]() Acousia Therapeutics GmbH BiotechnologyHealth Technology Acousia Therapeutics GmbH identifies small molecules for treatment of hearing loss. The firm develops drugs for local application, which will protect hearing function or restore hearing in patients who have lost their hearing ability due to various reasons. It also develops small molecule compounds that trigger regeneration of sensory hair cells and therefore allow casual treatment of sensorineural hearing loss in patients who already lost their hair cells years ago. The company was founded by Hubert Löwenheim and Karl-Heinz Wiesmüller in 2012 and is headquartered in Tübingen, Germany. | - |
Serena Preyer | F | - |
Acousia Therapeutics GmbH
![]() Acousia Therapeutics GmbH BiotechnologyHealth Technology Acousia Therapeutics GmbH identifies small molecules for treatment of hearing loss. The firm develops drugs for local application, which will protect hearing function or restore hearing in patients who have lost their hearing ability due to various reasons. It also develops small molecule compounds that trigger regeneration of sensory hair cells and therefore allow casual treatment of sensorineural hearing loss in patients who already lost their hair cells years ago. The company was founded by Hubert Löwenheim and Karl-Heinz Wiesmüller in 2012 and is headquartered in Tübingen, Germany. | - |
Gráfico relacional
Relaciones con varias empresas
Estadísticas
País | Relaciones | % del total |
---|---|---|
Alemania | 9 | 100.00% |
Antigüedad de la relación
Activas
Pasados
Hombre
Mujer
Administradores
Ejecutivos
Origen de las relaciones
- Bolsa de valores
- Insiders
- Christoph Arnoldner
- Red Personal